Managed Entry Agreements: The confidentiality issue
Managed Entry Agreements (MEAs) are contracts between pharmaceutical companies/…
Precision medicines: a value-based approach
Precision medicine is a novel and targeted approach for disease treatment and…
3D-printed drugs: the future of personalised medicine?
The aging population and the daily increase in the number of chronic diseases,…
Biosimilars: Enhancing physician uptake in the EU
At the moment, EU physicians seem much more comfortable than their US…
Human organoid models and their role in medical research
Human organoids are in vitro 3D biological structures that recapitulate…
Value-based healthcare, a new reality for everyone!
One of the biggest challenges in global healthcare is the rapidly increasing…
The future of Dengue vaccines
According to a WHO 2019 statement, Dengue fever is considered one of the top 10…
The patent landscape for a potential COVID-19 treatment
Introduction Since the outbreak of the COVID-19 pandemic began in 2020, it…
The environment does not need our antibiotics!
Every year around 100,000 tonnes of antibiotics are consumed globally. Out of…
For idiopathic pulmonary fibrosis treatment, a brighter future could be only a breath away
An overview of the disease Idiopathic pulmonary fibrosis (IPF) is a type of…
NFTs and healthcare, a match made in heaven(?)
What is an NFT? An NFT is a one-of-a-kind digital asset linked to blockchain*…
Get drugs out of the (sewage) system
A recent Netflix documentary, called Connected, highlighted the issue that many…
